Beta Drugs Limited (NSE:BETA)
1,699.25
-3.70 (-0.22%)
At close: Jul 24, 2025
Beta Drugs Revenue
In the fiscal year ending March 31, 2025, Beta Drugs had annual revenue of 3.62B INR with 22.54% growth. Beta Drugs had revenue of 1.82B in the half year ending March 31, 2025, with 58.69% growth.
Revenue
3.62B
Revenue Growth
+22.54%
P/S Ratio
4.76
Revenue / Employee
9.77M
Employees
371
Market Cap
17.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 3.62B | 666.42M | 22.54% |
Mar 31, 2024 | 2.96B | 686.00M | 30.21% |
Mar 31, 2023 | 2.27B | 432.76M | 23.54% |
Mar 31, 2022 | 1.84B | 677.16M | 58.31% |
Mar 31, 2021 | 1.16B | 253.16M | 27.88% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,729.85B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,429.39B |
Infosys | 1,672.76B |
Bajaj Finance | 370.20B |